Aromatase inhibitors are important for treating hormone receptor-positive breast cancer. This class of drugs – including anastrozole, letrozole, and exemestane – blocks the enzyme aromatase, which converts other hormones into estrogen. By lowering estrogen levels, they reduce the risk of the cancer coming back. According to the American Cancer Society, postmenopausal women with hormone receptor-positive disease typically take aromatase inhibitors for five to ten years after primary treatment.
This long treatment window poses a bone health challenge. Estrogen is central to bone maintenance. When AI therapy lowers estrogen, the balance between bone formation and bone breakdown shifts. Bone-removing cells called osteoclasts become more active, and women on this treatment lose bone mineral density (BMD) faster than those not taking the drug. For postmenopausal women who have already experienced some bone loss from natural menopause, this effect compounds existing risk.
| Intervention | Typical Protocol | Role and Notes |
|---|---|---|
| Calcium supplementation | Total daily intake (diet plus supplements) of 1,000-1,200 mg | Foundation of every bone health protocol during AI therapy; always combined with vitamin D |
| Vitamin D supplementation | 800-2,000 IU per day; baseline serum level check recommended | Needed for calcium absorption; dose adjusted based on blood 25-OH vitamin D level |
| Oral bisphosphonate (prescription) | Dose and schedule determined by oncologist | Antiresorptive agent; studied in multiple randomised trials; typically considered when T-score is at or below -2.0 |
| Intravenous zoledronic acid (prescription) | Infusion interval set by oncologist | Has preserved BMD in AI users in randomised trials, including the BATMAN trial |
| Denosumab (prescription) | Subcutaneous injection schedule set by oncologist | Antiresorptive; rebound bone loss can occur if stopped without a transition plan |
| Weight-bearing exercise | Regular activity on most days; type and amount guided by care team | Stimulates bone-forming cells; reduces fall risk through improved muscle strength and balance |
Calcium and vitamin D figures reflect the joint position statement from the International Osteoporosis Foundation and partner organisations: PMC5384888. Prescription agents require individual clinical assessment and a valid prescription.
How AI Therapy Affects Bone Density Over Time
Studies consistently show that AI therapy causes measurable decreases in bone mineral density, particularly in the first two to three years. Published evidence confirms that AI-associated bone loss is clinically distinct from natural menopausal bone loss and carries its own fracture risk. The hip and lumbar spine are most commonly affected – the sites a DEXA scan measures.
Women at higher risk include those who start AI therapy with already reduced bone density, who smoke, who have a family history of osteoporosis, or who have low body weight. A joint position statement from the International Osteoporosis Foundation and partner organisations shows that elevated bone turnover markers – blood and urine tests that reflect bone breakdown – can rise within weeks of starting an AI. The effect on bone metabolism begins early, not gradually over years.
Monitoring Bone Health: Starting with a DEXA Scan
A DEXA scan is the standard test for measuring bone mineral density. Guidelines recommend a baseline DEXA scan for all patients starting AI therapy to track any changes. The scan measures BMD at the hip and lumbar spine and produces a T-score, which compares your bone density to that of a healthy young adult at peak bone mass.
A T-score at or below -2.0 at any measured site is a key threshold that may lead an oncologist to consider a prescription bone-protective agent. When T-scores are borderline but other risk factors are present, oncologists also use the FRAX calculator – a World Health Organization tool – to estimate the 10-year probability of a major or hip fracture. Doctors typically arrange repeat DEXA scans every one to two years during treatment.
For women at the start of breast cancer treatment, the article Newly Diagnosed with Hormone-Positive Breast Cancer: Reading Your Pathology Report and Planning Integrative Support covers what to ask your oncology team when building a comprehensive treatment plan, including bone health monitoring from day one.
Calcium and Vitamin D: The Foundation
All patients starting AI therapy should take calcium and vitamin D supplements, regardless of baseline bone density. These two nutrients work together: calcium is the primary mineral in bone, and vitamin D controls how well your intestines absorb it. Without enough vitamin D, your body may not use calcium well.
The joint position statement from the International Osteoporosis Foundation recommends getting 1,000 to 1,200 mg of calcium daily from food and supplements combined. For vitamin D, the statement recommends a minimum of 800 IU per day, with up to 2,000 IU per day for those with confirmed deficiency or elevated fracture risk. Checking a baseline serum 25-hydroxyvitamin D level is a practical first step because deficiency is common and easy to fix.
These nutrients form the foundation, but most women with low T-scores or elevated FRAX risk will also need a prescription antiresorptive agent. The same joint position statement notes that calcium and vitamin D supplements alone do not reduce fracture risk in women with breast cancer on AI therapy.
Prescription Antiresorptive Agents
When bone density or fracture risk crosses clinical thresholds, oncologists may consider prescription antiresorptive medications. These agents reduce osteoclast activity, slow bone breakdown, and preserve or improve BMD in women on AI therapy, according to randomised trials.
Bisphosphonates are the most extensively studied class for this purpose. Options include oral agents like alendronate and risedronate, or intravenous agents like zoledronic acid. The BATMAN trial found that zoledronic acid preserved bone mineral density in postmenopausal women with early breast cancer receiving AI therapy. Research also shows that bisphosphonates help preserve BMD in women on AI therapy. Your oncologist chooses the specific agent, dose, and schedule based on your T-score, FRAX risk, kidney function, and how well you tolerate it.
Denosumab is a second prescription option. It works by blocking RANK ligand, a protein that drives osteoclast formation. Unlike bisphosphonates, you need to continue it on a regular schedule – stopping it abruptly can trigger rebound bone loss, so any change requires a planned transition. Both bisphosphonates and denosumab have been shown to help protect bone during AI therapy. Your oncologist is the best person to advise on which option suits your situation.
Weight-Bearing Exercise and Fall Prevention
Physical activity helps bone health during long-term AI therapy. Weight-bearing exercises – activities that require your body to work against gravity – stimulate bone-forming cells called osteoblasts. Walking, resistance training, low-impact aerobics, and balance work like tai chi all fall into this category. Resistance training in particular helps both bone density and muscle mass, which lowers your risk of falls – the most common cause of fractures when bone density is low.
Hormone suppression therapy affects bone health in many types of cancer. Resistance training for bone preservation during hormone suppression is discussed in Prostate Cancer and Androgen Deprivation Therapy: Bone Health, Vitamin D Dosing, and Resistance Training. Many of the same exercise principles apply to AI therapy too. Always talk to your care team before starting a new exercise program or changing your current routine, especially if you have joint problems.
Other Modifiable Factors
Several additional lifestyle factors can influence bone health and fracture risk during AI therapy:
- Smoking: Smoking speeds up bone loss and reduces calcium absorption. Quitting at any time helps.
- Alcohol: High alcohol intake raises fracture risk. Try to have no more than one drink a day for bone health.
- Dietary calcium: Getting calcium from food – dairy products, fortified plant milks, leafy greens like kale, and tinned fish with soft bones – adds to your total calcium alongside supplements.
- Fall prevention: Non-slip flooring, good lighting in your home, and reviewing medications that affect balance lower fracture risk regardless of your bone density scores.
Aromatase inhibitors also commonly cause joint and muscle pain, which can make it hard to stay active. Evidence on anti-inflammatory supplements for AI-related joint pain – including how much was used in clinical trials – is covered in Aromatase Inhibitor Joint Pain and Curcumin Dosing.
Bringing It Together
Protecting bone health during long-term AI therapy works best when you start multiple strategies early. A practical approach includes getting a baseline DEXA scan and vitamin D level check at or near the time you start AI therapy, getting 1,000 to 1,200 mg of calcium and at least 800 IU of vitamin D daily, doing weight-bearing activities regularly, and checking your bone density with your oncologist each year to see if you need bone-protecting medication based on your risk.
Nutraceuticals to support bone health are available in the Oncostore Nutraceuticals category for those interested in supplement options during long-term cancer treatment.
If you are on prescription medication, pregnant, or breastfeeding, discuss any supplement changes with your clinician before starting them. This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
